There have been a number of new treatments for multiple sclerosis (MS) patients over the last couple of decades, but diagnostic tools in the MS space has lagged behind, at least when it comes to measuring biofluids to confirm suspected MS based on MRI images. One company, DioGenix (Gaithersburg, Maryland), thinks it has found an easier way to identify patients with MS at first clinical presentation, and also rule out MS for patients who don't have the disease.